02/17/2023 | 01:21am EST Redeye makes minor adjustments to its estimates but maintains its fair value range and base case. The Q4 2022 report presented a strong order intake, new partnership agreements and upselling, but also a churn of 10%.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye – Research Powered Investment Banking. www.redeye.se/


crocon media is owned by the sillc assembly. This site is for entertainment purposes only. The owner of this site is not an investment advisor, financial planner, nor legal or tax professional and articles here are of an opinion and general nature and should not be relied upon for individual circumstances.

Editorial Disclosure: The editorial content on this page is not provided by any entity mentioned herein. Opinions expressed here are the author’s alone, and have not been reviewed, approved or otherwise endorsed by any of these entities.

Follow Us